Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

Although metabolic syndrome is associated with higher PsA disease activity, it is not associated with higher PsA-related ...

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

A new study suggests that people with arthritis may be more likely to have overactive bladder (OAB), a condition that causes ...

Biologic disease-modifying antirheumatic drugs (bDMARDs) do not appear to negatively impact fertility among women with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), according to study ...

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Positive association seen between osteoarthritis and OAB, but not for rheumatoid arthritis or psoriatic arthritis ...

Squibb announced positive data from the Phase 3 POETYK PsA-2 trial evaluating the efficacy and safety of Sotyktu in adults ...